Clinical Trial

Mini-dose Dexmedetomidine-Esketamine Supplemented Analgesia in Patients at High-risk of OSA

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 25, 2024 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
Patients with obstructive sleep apnea (OSA) are at increased risk of developing sleep disturbances after surgery. Dexmedetomidine is a highly selective α2-adrenergic agonist with sedative, analgesic, and anxiolytic effects. Ketamine is a noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist. Esketamine is the S-enantiomer of racemic ketamine and twice as potent as racemic ketamine for analgesia. A recent trial showed that mini-dose esketamine-dexmedetomidine in combination with opioids improved analgesia and subjective sleep quality after scoliosis correction surgery. This trial is designed to test the hypothesis that mini-dose dexmedetomidine-esketamine supplemented analgesia may improve postoperative sleep quality in patients at high-risk of OSA.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-20.
Status change: Not Yet Recruiting → Recruiting 2024-09-23
Trial Details
NCT Number NCT06566482
Lead Sponsor Peking University First Hospital
Conditions Obstructive Sleep Apnea, Surgery, Dexmedetomidine, Esketamine, Postoperative Sleep Quality
Enrollment 100 participants
Start Date 2024-09-11
Primary Completion 2025-09 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-09-25